Chronic Myelogenous Leukemia, Ph1-Positive

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bio-Path Holdings
Bio-Path HoldingsBELLAIRE, TX
1 program
1
BP1001Phase 1/21 trial
Active Trials
NCT02923986Withdrawn0Est. May 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bio-Path HoldingsBP1001

Clinical Trials (1)

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Start: Sep 2017Est. completion: May 20200
Phase 1/2Withdrawn

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space